p.99 抽出テキスト
857. Dohler I, Roder D, Schlesinger T, Nassen CA, Germer CT, Wiegering A, et al. Risk-adjusted perioperative bridging anticoagulation reduces bleeding complications without increasing thromboembolic events in general and visceral surgery. BMC Anesthesiol 2023;23:56. https://doi.org/10.1186/s12871-023-02017-z 858. Shah S, Nayfeh T, Hasan B, Urtecho M, Firwana M, Saadi S, et al. Perioperative management of vitamin K antagonists and direct oral anticoagulants: a systematic review and meta-analysis. Chest 2023;163:1245–57. https://doi.org/10.1016/j.chest.2022.11. 032 859. Gigante B, Tamargo J, Agewall S, Atar D, Ten Berg J, Campo G, et al. Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. Eur Heart J Cardiovasc Pharmacother 2024;10:614–45. https://doi.org/10. 1093/ehjcvp/pvae064 860. Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JK, et al. 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg 2024;67:ezae355. https://doi.org/10.1093/ejcts/ezae355 861. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ 2021;373:n1205. https://doi.org/10.1136/bmj.n1205 862. Kuo HC, Liu FL, Chen JT, Cherng YG, Tam KW, Tai YH. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol 2020;43:441–9. https://doi.org/10.1002/clc.23336 863. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630–9. https://doi.org/10.1161/CIRCULATIONAHA.112.105221 864. Yong JW, Yang LX, Ohene BE, Zhou YJ, Wang ZJ. Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017;17:295. https://doi.org/10.1186/s12872-017-0719-7 865. Brennan JM, Edwards FH, Zhao Y, O’Brien S, Booth ME, Dokholyan RS, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012; 60:971–7. https://doi.org/10.1016/j.jacc.2012.05.029 866. Rafiq S, Steinbrüchel DA, Lilleør NB, Moller CH, Lund JT, Thiis JJ, et al. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017;150:104–10. https://doi.org/10.1016/j. thromres.2016.11.021 867. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S. Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 2013;112:1439–44. https://doi.org/10.1016/j.amjcard.2013.06. 014 868. Russo A, Grigioni F, Avierinos JF, Freeman WK, Suri R, Michelena H, et al. Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008;51:1203–11. https://doi.org/10.1016/j.jacc.2007.10.058 869. Dangas GD, Tijssen JGP, Wöhrle J, Sondergaard L, Gilard M, Mollmann H, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020;382:120–9. https://doi.org/10.1056/NEJMoa1911425 870. Alkhalil M, Edwards R, Puri R, Kalra A, Zaman A, Das R. Aspirin versus dual antiplatelet therapy in patients undergoing trans-catheter aortic valve implantation, updated meta-analysis. Cardiovasc Drugs Ther 2022;36:279–83. https://doi.org/10.1007/ s10557-021-07146-6 871. El Bèze N, Himbert D, Suc G, Brochet E, Ajzenberg N, Cailliau A, et al. Comparison of direct oral anticoagulants vs vitamin K antagonists after transcatheter mitral valve replacement. J Am Coll Cardiol 2024;83:334–46. https://doi.org/10.1016/j.jacc.2023.10. 031 872. Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, et al. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135:1273–5. https://doi.org/10.1161/ CIRCULATIONAHA.116.026714 873. Guimarães HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117–26. https://doi.org/10.1056/NEJM oa2029603 874. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, et al. Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project. Thromb Haemost 2016;115:1056–63. https://doi.org/10.1160/TH16-01-0007 875. Shim CY, Seo J, Kim YJ, Lee SH, De Caterina R, Lee S, et al. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 2023;165:58–67.e54. https://doi.org/ 10.1016/j.jtcvs.2021.01.127 876. Siontis KC, Yao X, Gersh BJ, Noseworthy PA. Direct oral anticoagulants in patients with atrial fibrillation and valvular heart disease other than significant mitral stenosis and mechanical valves: a meta-analysis. Circulation 2017;135:714–6. https://doi.org/ 10.1161/CIRCULATIONAHA.116.026793 877. Suppah M, Kamal A, Saadoun R, Baradeiya AMA, Abraham B, Alsidawi S, et al. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol 2023;206:132–50. https://doi.org/10.1016/j.amjcard.2023.07.141 878. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;382:1696–707. https://doi.org/10.1056/NEJMoa1915152 879. Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, Lopez-Otero D, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 2021;385:2150–60. https://doi.org/10.1056/NEJMoa2111016 880. Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J 2022;43:2783–97. https://doi.org/10.1093/eurheartj/ehac242 881. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020;383:1447–57. https://doi.org/10.1056/NEJMoa2017815 882. Maes F, Stabile E, Ussia GP, Tamburino C, Pucciarelli A, Masson JB, et al. Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol 2018;122:310–5. https://doi.org/10.1016/j.amjcard.2018. 04.006 883. Rodés-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv 2017;10:1357–65. https://doi.org/10.1016/j.jcin.2017.04.014 884. Meurin P, Tabet JY, Iliou MC, Pierre B, Corone S, Cristofini P, et al. Thromboembolic events early after mitral valve repair: incidence and predictive factors. Int J Cardiol 2008; 126:45–52. https://doi.org/10.1016/j.ijcard.2007.03.115 885. van der Wall SJ, Olsthoorn JR, Heuts S, Klautz RJM, Tomsic A, Jansen EK, et al. Antithrombotic therapy after mitral valve repair: VKA or aspirin? J Thromb Thrombolysis 2018;46:473–81. https://doi.org/10.1007/s11239-018-1724-0 886. Mazur PK, Arghami A, Macielak SA, Nei SD, Viehman JK, King KS, et al. Apixaban for anticoagulation after robotic mitral valve repair. Ann Thorac Surg 2023;115:966–73. https://doi.org/10.1016/j.athoracsur.2022.07.045 887. Paparella D, Di Mauro M, Bitton Worms K, Bolotin G, Russo C, Trunfio S, et al. Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair. J Thorac Cardiovasc Surg 2016;151:1302–8.e1301. https://doi.org/10. 1016/j.jtcvs.2015.12.036 888. Trevis J, Akowuah E. Which antithrombotic strategy provides the best outcomes after mitral valve repair in patients who remain in sinus rhythm? Interact Cardiovasc Thorac Surg 2022;35:ivac085. https://doi.org/10.1093/icvts/ivac085 889. Moser N, Omar MA, Koshman SL, Lin M, Youngson E, Kent W, et al. Direct oral anticoagulants for atrial fibrillation in early postoperative valve repair or bioprosthetic replacement. J Thorac Cardiovasc Surg 2023;168:523–32.e3. https://doi.org/10.1016/j. jtcvs.2023.03.004 890. Mentias A, Saad M, Michael M, Nakhla S, Menon V, Harb S, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc 2022;11:e026666. https://doi.org/10.1161/jaha.122.026666 891. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, et al. Prognostic value of CHA2DS2-VASc score in patients with ‘non-valvular atrial fibrillation’ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 2015;36:1822–30. https://doi.org/10.1093/eurheartj/ehv163 892. Jochheim D, Barbanti M, Capretti G, Stefanini GG, Hapfelmeier A, Zadrozny M, et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2019;12:1566–76. https://doi.org/10.1016/j.jcin.2019.03.003 893. Didier R, Lhermusier T, Auffret V, Eltchaninoff H, Le Breton H, Cayla G, et al. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist? JACC Cardiovasc Interv 2021;14:1704–13. https://doi.org/10.1016/j.jcin.2021.05.025 894. Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS/ACC TVT registry. J Am Heart Assoc 2022;11:e023561. https://doi.org/10.1161/jaha.121.023561 895. VARC-3 Writing Committee; Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 2021;77:2717–46. https://doi.org/10.1016/j.jacc. 2021.02.038 896. Pibarot P, Herrmann HC, Wu C, Hahn RT, Otto CM, Abbas AE, et al. Standardized definitions for bioprosthetic valve dysfunction following aortic or mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol 2022;80:545–61. https://doi.org/ 10.1016/j.jacc.2022.06.002 897. Kaneko T, Bapat VN, Alakhtar AM, Zaid S, George I, Grubb KJ, et al. Transcatheter heart valve explantation for transcatheter aortic valve replacement failure: a Heart ESC Guidelines 4733 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026